trial · primary record
IKS03
B-cell Non-Hodgkin Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 140 |
| Primary completion | 2028-09 |
| Primary endpoint | Recommended Phase 2 Dose (Part I) |
| Registry ID | NCT05365659 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:46.712Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05365659
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.